Daiichi-Sankyo and AstraZeneca Enhertu4U Support Program
Daiichi-Sankyo and AstraZeneca offer the Enhertu4U support program to provide information and assistance to patients who have been prescribed Enhertu (Table).
Enhertu4U Support Program
Patient Savings Program
Eligible patients may pay as little as $0 per Enhertu prescription, up to $26,000 per calendar year.
Patient Assistance Programs
The Patient Assistance Programs provide Enhertu at no cost to qualifying uninsured, underinsured, or Medicare patients who are having financial difficulty affording their medication.
If the patient has experienced a life-changing event in the past year, and financial documentation does not accurately reflect the current situation, the patient may still meet the criteria to enroll and is encouraged to apply.
To view eligibility criteria and enroll your patient, visit Patient Assistance Programs.
Product Request Form
For patients already enrolled in the Patient Assistance Program, the product request form may be used to request the patient’s next dose of Enhertu. The form can be accessed Product Request Form.
Assistance may also be available through independent foundations. Although not associated with Daiichi-Sankyo or AstraZeneca, names and links to several foundations are available online.
TABLE Daiichi-Sankyo and AstraZeneca’s Oncology Drug
- adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
- in the metastatic setting, or
- in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
- Adult patients with unresectable or metastatic HER2-low breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
- Adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
- Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.